The Burden of Mitochondrial Disease: Healthcare and Societal Costs
Mitochondrial disease is an expensive condition with the majority of the costs comprising societal costs, with substantial costs borne privately out of pocket. The findings from this study can be used in other studies, such as cost-effectiveness analysis, to examine the benefits of interventions to treat or prevent mitochondrial disease.
Authors
- Sarah West (ORCID: https://orcid.org/0000-0001-8516-4140)
- Jayamala Parmar
- Sameen Haque (ORCID: https://orcid.org/0000-0002-6204-6640)
- Carolyn M. Sue (ORCID: https://orcid.org/0000-0003-1255-3617)
- DEBORAH J. SCHOFIELD (ORCID: https://orcid.org/0000-0002-1658-494X)
- Joshua Kraindler (ORCID: https://orcid.org/0000-0003-2103-6726)
- Owen Tan (ORCID: https://orcid.org/0000-0002-0303-7138)
- Karen Crawley
- Katherine K. Lim (ORCID: https://orcid.org/0000-0001-9960-6878)
- Rupendra N. Shrestha (ORCID: https://orcid.org/0000-0001-5455-0735)
- Adam Percival
Institutions
- UNSW Sydney (AU)
- Neuroscience Research Australia (AU)
- Macquarie University (AU)
Publication Details
- Journal
- Value in Health
- Published
- 2025-06-07
- DOI
- https://doi.org/10.1016/j.jval.2025.05.016
- Citations
- 1
- Primary Topic
- Health, Environment, Cognitive Aging
- Type
- article
- Field-Weighted Citation Impact
- 1.20
Funders
- National Health and Medical Research Council